AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...
Dealbreaker on MSN14h
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec AcquisitionAstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback